Hepion Pharmaceuticals, INC

Hepion Pharmaceuticals, Inc. has dismissed its independent registered public accounting firm, Grassi & Co., CPAs, P.C., and engaged Rosenberg Rich Baker Berman P.A. as its new auditor.

Hepion Pharmaceuticals, Inc. has issued a $500,000 senior secured convertible promissory note to Gravitas Capital LP, with a maturity date of September 3, 2027, and includes a warrant for common stock purchase.

Hepion Pharmaceuticals announced a private placement of common stock and warrants, raising $400,000 at $0.05 per share.

Hepion Pharmaceuticals, Inc. announced the immediate appointment of James Liddy to its Board of Directors, effective August 19, 2026.

Hepion Pharmaceuticals, Inc. has entered into securities purchase agreements to sell shares and warrants in a private placement, raising gross proceeds of $3,055,000.

Hepion Pharmaceuticals, Inc. announced the immediate appointment of Danina Fisher and Gary S. Stetz, II to its Board of Directors.

Hepion Pharmaceuticals' Q2 2026 report highlights significant operating losses, a substantial accumulated deficit, and material weaknesses in internal controls, raising concerns about its ability to continue as a going concern despite recent financing.

Hepion Pharmaceuticals reports Q1 2026 results with reduced operating expenses but continues to face going concern uncertainties, while also announcing a new diagnostic asset license.

Hepion Pharmaceuticals shifts focus to medical diagnostics after winding down its liver disease drug program, reporting reduced net losses and improved cash position despite Nasdaq delisting.

Hepion Pharmaceuticals shifts from drug development to diagnostics after clinical trial wind-down and failed merger, securing new licenses while navigating Nasdaq delisting and persistent financial challenges.

Hepion Pharmaceuticals reports Q1 2025 results, including a net loss of $6.1 million, and enters into a license agreement with New Day Diagnostics for certain diagnostic tests.

Hepion Pharmaceuticals reported its Q3 2024 results, highlighting a significant decrease in operating expenses and ongoing strategic restructuring efforts, including a planned merger with Pharma Two B Ltd.

Hepion Pharmaceuticals reports significant losses and going concern doubt, pivoting from drug development to diagnostic tests after winding down its lead clinical trial and delisting from Nasdaq.

Hepion Pharmaceuticals reports its 2024 financial results, highlighting a strategic restructuring, termination of a merger agreement, and substantial doubt about its ability to continue as a going concern.

Hepion Pharmaceuticals has filed an amendment to its Form 10-K/A to correct errors in executive compensation and security ownership information.

Hepion Pharmaceuticals has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Hepion Pharmaceuticals' 2023 annual report details a strategic restructuring plan to preserve capital, ongoing clinical trials for rencofilstat, and financial losses.

Vincent S Lopriore, Executive Chairman and a Director of Hepion Pharmaceuticals, Inc., purchased 12,500,000 shares of common stock on September 3, 2026.

Michael J. Purcell, a Director of Hepion Pharmaceuticals, Inc., received 299,000 shares of common stock on August 19, 2026.

Gary S. Stetz, Interim CEO and a Director of Hepion Pharmaceuticals, Inc., received 1,345,500 shares of common stock on August 19, 2026.

Chase Lopriore, VP, Corp. Dev. and a Director of Hepion Pharmaceuticals, Inc., received 1,345,500 shares of common stock on August 19, 2026.

Danina Fisher, a Director of Hepion Pharmaceuticals, Inc., received 299,000 shares of common stock on August 19, 2026.

James Gordon Liddy, a Director of Hepion Pharmaceuticals, Inc., received 299,000 shares of common stock on August 19, 2026.

Hepion Pharmaceuticals has issued its 2026 proxy statement detailing director elections, auditor ratification, and a significant expansion of its equity incentive plan.

Hepion Pharmaceuticals is holding its annual meeting on June 12, 2025, seeking stockholder approval for key proposals including a reverse stock split and the election of directors.

Hepion Pharmaceuticals is asking stockholders to vote on key proposals at its annual meeting, including a reverse stock split and approval for the issuance of shares related to warrant exercises.

Pharma Two B presented positive integrated safety and efficacy data for its Parkinson's disease drug, P2B001, and is progressing towards a merger with Hepion Pharmaceuticals.

Hepion Pharmaceuticals is urging its shareholders to vote in favor of a proposed merger with Pharma Two B, citing financial challenges and the potential upside of Pharma Two B's Parkinson's disease treatment.

Hepion Pharmaceuticals is registering an additional $3 million in securities, including common stock and warrants, following a previous registration.

Hepion Pharmaceuticals plans to offer shares of common stock, pre-funded warrants, and common stock purchase warrants in a reasonable best efforts offering.

Hepion Pharmaceuticals is conducting a public offering of common stock and warrants to raise capital, primarily to repay outstanding debt and for general corporate purposes, following a terminated merger agreement and ongoing Nasdaq compliance issues.

Hepion Pharmaceuticals is registering for the resale of up to 1,470,590 shares of its common stock by a selling stockholder, potentially generating $2.8 million in gross proceeds for the company upon warrant exercises.

KI Holdings Ltd., through Donald Kivowitz, has acquired a 10.2% stake in Hepion Pharmaceuticals, Inc. via a private placement involving common stock and warrants.

Vincent LoPriore, Gravitas Capital LP, and Invictus Capital Advisors Pension Plan collectively increased their beneficial ownership of Hepion Pharmaceuticals, Inc. common stock to 26.2%.

A key executive at Hepion Pharmaceuticals has increased their beneficial ownership to 5.7% through recent stock and warrant purchases, signaling continued personal investment in the company.

Gary Stetz, interim CEO and director of Hepion Pharmaceuticals, has increased his beneficial ownership to 5.7% through recent share and warrant purchases.

Black Global 5 LLC, Red Global 3, LLC, and Darin Feinstein have jointly filed a Schedule 13D, reporting beneficial ownership of 10,000,000 shares of Hepion Pharmaceuticals, Inc. common stock, representing 11.1% of the class.

Executive Chairman Vincent LoPriore and affiliated entities report a combined 21.46% beneficial ownership stake in Hepion Pharmaceuticals, Inc.

Kenneth Rickel has filed a Schedule 13G, reporting beneficial ownership of 5,250,000 shares, representing 5.7% of Hepion Pharmaceuticals' outstanding common stock.

Anson Funds Management LP and related entities reported a 4.9% beneficial ownership stake in Hepion Pharmaceuticals, Inc., including shares from warrants.

S.H.N. Financial Investments Ltd. has amended its Schedule 13G, reporting zero beneficial ownership in Hepion Pharmaceuticals, Inc.

Anson Funds Management LP and its affiliates have reported a 9.9% beneficial ownership stake in Hepion Pharmaceuticals, Inc., primarily for investment purposes.

S.H.N. Financial Investments Ltd. has reported a 9.99% beneficial ownership stake in Hepion Pharmaceuticals, Inc., including shares acquired through a recent offering.

Bigger Capital Fund, along with its general partner and managing member, reported a 9.99% beneficial ownership in Hepion Pharmaceuticals before selling all shares, excluding those issuable upon warrant exercise, by January 24, 2025.